Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

Introduction: In recent years, target therapies to specific molecular alterations in advanced non–small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheles...

Full description

Bibliographic Details
Main Authors:	Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo
Format:	Article
Language:	English
Published:	AboutScience Srl 2022-09-01
Series:	Global & Regional Health Technology Assessment
Subjects:	ALK Cost-benefit Cost-effectiveness Economic evaluation Lung cancer Non–small cell lung cancer
Online Access:	https://journals.aboutscience.eu/index.php/grhta/article/view/2449

Similar Items

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
by: Rothschild SI
Published: (2016-05-01)

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
by: Wenjie Liu, et al.
Published: (2024-02-01)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
by: Fangfang Gao, et al.
Published: (2022-04-01)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
by: Deng L, et al.
Published: (2018-09-01)

Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics
by: Ilija Nenadić, et al.
Published: (2017-07-01)

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain
by: Presa M, et al.
Published: (2023-09-01)

New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)—Positive Cancer
by: Matteo Villa, et al.
Published: (2021-10-01)

ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice
by: Paul Hofman
Published: (2017-08-01)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
by: Emilio Francesco Giunta, et al.
Published: (2022-06-01)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
by: Ming-Hung Huang, PhD, et al.
Published: (2022-11-01)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
by: Kunyan Sun, et al.
Published: (2021-06-01)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
by: Zhe-Rong Zheng, et al.
Published: (2023-03-01)

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene
by: Zachary R. Schoepflin, MD, et al.
Published: (2023-04-01)

SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report
by: Lin Ma, et al.
Published: (2022-03-01)

EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report
by: Stefan Diem, et al.
Published: (2013-06-01)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
by: Barrows SM, et al.
Published: (2019-02-01)

ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors
by: Elena Corral de la Fuente, et al.
Published: (2021-12-01)

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
by: Min Zhang, MBBS, et al.
Published: (2021-02-01)

Treatment of Patients with ALK-positive Non-small Cell Lung Cancer  and Brain Metastases
by: Jialin LV, et al.
Published: (2016-08-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
by: Jing ZHAO, et al.
Published: (2015-10-01)

Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
by: Rui Kitadai, et al.
Published: (2019-02-01)

Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review
by: Zhichao Liu, et al.
Published: (2018-01-01)

Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer
by: K. K. Laktionov, et al.
Published: (2019-06-01)

Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001
by: Terry L. Ng, et al.
Published: (2022-12-01)

Current approaches to therapy of ALK-positive non-small cell lung cancer
by: К. К. Laktionov, et al.
Published: (2021-06-01)

Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations
by: Marcus Rathbone, et al.
Published: (2024-03-01)

A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors  and Chemotherapy
by: Jue WANG, et al.
Published: (2021-05-01)

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer
by: Jin Kang, et al.
Published: (2020-12-01)

Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC
by: Federica Zito Marino, et al.
Published: (2020-07-01)

PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK‐rearranged lung cancer
by: Sarang S. Talwelkar, et al.
Published: (2023-05-01)

Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group
by: Wenbin Li, et al.
Published: (2021-12-01)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01)

Experience of targeted therapy for ALK positive non-small cell lung cancer – a clinical case
by: A. V. Sultanbaev, et al.
Published: (2020-12-01)

Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions
by: Hannaneh Parvaresh, et al.
Published: (2024-01-01)

A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
by: Bei Zheng, et al.
Published: (2023-08-01)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
by: Ling Peng, et al.
Published: (2022-04-01)

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
by: SiNi Li, et al.
Published: (2021-05-01)

ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review
by: Zhu Zeng, et al.
Published: (2022-10-01)

ALK Mutation Status in EGFR-negative Non-small-cell Lung Cancer Patients in Bulgaria
by: Djambazov Slaveyko N., et al.
Published: (2018-09-01)